| |

IMRT for Mesothelioma: Barriers to Completing Treatment

ByAlex Strauss
IMRT for mesothelioma

MD Anderson researchers say too many patients who might benefit from IMRT for mesothelioma never complete the treatment. The problem could be impacting their survival.

Intensity Modulated Radiotherapy (IMRT) is a type of targeted radiation. It is designed to direct as much radiation as possible into the mesothelioma tumor without harming the surrounding tissue. 

Patients who have a combination of surgery, chemotherapy, and IMRT for mesothelioma have the best odds of survival.

But at MD Anderson Cancer Center, only two thirds of eligible patients completed IMRT after mesothelioma surgery. The new study aimed to find out why.

Trimodal Therapy and Mesothelioma Survival

Malignant mesothelioma rarely responds to a single cancer therapy. Trimodal therapy combines several different treatments to maximize success. 

A 2017 MD Anderson study found that trimodal therapy including IMRT for mesothelioma extended survival by nearly nine months. Epithelioid mesothelioma patients who had this treatment lived an average of 23.4 months. 

Mesothelioma patients may have radiation for different reasons. Sometimes, it is used to shrink a tumor before surgery. Sometimes, radiation is used to relieve symptoms. 

Radiation delivered after surgery is called adjuvant radiotherapy. The new study focuses only on adjuvant IMRT for mesothelioma.

Why Some Patients Do Not Complete IMRT for Mesothelioma

The newest MD Anderson study included 160 pleural mesothelioma patients diagnosed between 2004 and 2017. About 60 percent of them had extrapleural pneumonectomy. The other 40 percent had lung-sparing pleurectomy/decortication.

All of the patients were candidates for adjuvant IMRT for mesothelioma. But only 66 percent of them completed the treatment. 

In 19 cases, this was because the patient died before they could start radiotherapy. For 21 patients, the radiation dose they needed caused too many side effects. 

In the remaining patients, either surgery complications, delayed recovery, or an unknown reason kept them from completing IMRT for mesothelioma. 

Patients with the most advanced disease going in and those with a history of smoking were less likely to complete IMRT. 

Age and Surgery Type Have Little Impact on IMRT Success

Surprisingly, other factors – like age and surgery type – had little impact on the completion of IMRT for mesothelioma. 

“Extrapleural pneumonectomy or pleurectomy/decortication, margin status, age, and histology, were not associated with receiving adjuvant intensity-modulated radiation therapy,” writes lead author David B. Nelson. 

The question of IMRT completion is worth exploring, especially among patients with early-stage mesothelioma. Nelson and his team published another study on IMRT for mesothelioma earlier this year. That study used data from the National Cancer Database. It found that early-stage patients had the best results with trimodal treatment. 

“Adjuvant radiation was associated with improved survival among those who were stage I-II (P=0.024), but not stage III or IV,” wrote Dr. Nelson. Patients in the later stages of mesothelioma lived for about the same amount of time as those who did not have any adjuvant radiotherapy. 

Sources: 

Nelson, DB, et al, “Return to intended oncologic treatment after surgery for malignant pleural mesothelioma”, September 2019, Journal of Thoracic and Cardiovascular Surgery, Epub ahead of print, https://www.ncbi.nlm.nih.gov/pubmed/31430846

Nelson, DB, et al, “Defining the role of adjuvant radiotherapy for malignant pleural mesothelioma: a propensity-matched landmark analysis of the National Cancer Database”, April 2019, Journal of Thoracic Disease, pp. 1269-1278, http://jtd.amegroups.com/article/view/28310/20869

Similar Posts

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    ByAlex Strauss

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    ByAlex Strauss

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • | |

    Radiotherapy for Mesothelioma: Better But Still Limited

    ByAlex Strauss

    A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…

  • | |

    A Second-Line Option for Mesothelioma?

    ByAlex Strauss

    Although survival was not significantly extended, the chemotherapy drug vinorelbine might be a treatment option for mesothelioma patients whose cancer has returned after first-line chemotherapy with pemetrexed. A new study on vinorelbine as a second-line treatment finds that the drug is “moderately active” in mesothelioma patients who were initially treated with pemetrexed-based chemotherapy. Pemetrexed (Alimta), along with a platinum-based drug like cisplatin, is the primary first-line drug therapy for mesothelioma. But vinorelbine is gaining attention as a possible option for mesothelioma, in part because it is available in a less expensive generic form. In “Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma”, the Italian authors detail the results of their study on 59 patients with unresectable pleural mesothelioma.  These patients…

  • | |

    Repeat HIPEC Improves Mesothelioma Survival

    ByAlex Strauss

    If one cytoreductive surgery and HIPEC procedure for mesothelioma is good, subsequent treatments may be even better. That is the central message of research conducted at the Moffitt Cancer Center in Florida. The study’s aim was to assess overall survival among peritoneal mesothelioma patients who had not just one, but two or more rounds of heated intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery. The cytoreduction/HIPEC approach has become popular for peritoneal mesothelioma, a treatment-resistant cancer of abdominal membranes caused by asbestos. Cytoreductive surgery involves removing as much of the mesothelioma tumor as possible from the abdomen. Because the shape and spreading pattern of mesothelioma tumors make complete cytoreduction difficult, the surgery is often followed by a rinse with a heated solution…

  • | |

    Value of Mesothelioma Surgery Challenged for Healthy Patients

    ByAlex Strauss

    New research conducted in Italy and presented at the 15th World Conference on Lung Cancer in Sydney, Australia suggests that mesothelioma surgery – no matter what kind – may not offer a survival advantage over medical management for the healthiest of patients. Mesothelioma is a rare but aggressive malignancy that is highly resistant to standard cancer treatments. The two types of mesothelioma surgery considered to be options for people with resectable cancer are pleurectomy decortication (P/D) or extrapleural pneumonectomy (EPP). While EPP is more radical than P/D because it involves removing a lung, both carry a heavy risk of complications and, according to the Italian researchers, may not be of value for certain patients. The study reviewed data from 1,365…